18. Spinocerebellar degeneration
59 clinical trials,   78 drugs   (DrugBank: 28 drugs),   44 drug target genes,   59 drug target pathways

Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04519567
(ClinicalTrials.gov)
July 31, 202017/8/2020Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCRecruiting18 YearsN/AAll30Phase 1United States
2NCT04176991
(ClinicalTrials.gov)
December 11, 201914/11/2019Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCCompleted18 YearsN/AAll28Phase 1United States